Cara Therapeutics Inc (NAS:CARA)
$ 0.378 -0.0719 (-15.98%) Market Cap: 20.73 Mil Enterprise Value: -13.94 Mil PE Ratio: 0 PB Ratio: 37.80 GF Score: 35/100

Cara Therapeutics Inc KORSUVA™ Injection Approval Conference Call Transcript

Aug 23, 2021 / 09:00PM GMT
Release Date Price: $14.28 (+4.23%)
Operator

Good afternoon, and welcome to the Cara Therapeutics KORSUVA Injection FDA Approval Conference Call. (Operator Instructions) There will be a question-and-answer session at the end. Please be advised that this call is being recorded at Cara's request.

I will now turn the call over to the Cara team. Please proceed.

Will Gramig

Good afternoon. This is Will Gramig with Stern Investor Relations, and welcome to Cara Therapeutics' KORSUVA Injection FDA Approval Conference Call. The news release became available just before 4 p.m. today and can be found on our website at www.caratherapeutics.com. You may also listen to a live webcast and replay of today's call on the Investors section of the website.

Before we begin, let me remind you that statements made on today's call regarding matters that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Examples of these forward-looking statements include statements

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot